Benchling gave its R&D tool free to academic labs, then sold enterprise labs on it

Benchling sells life sciences R&D software that replaces paper lab notebooks and spreadsheets with a platform for tracking samples, notebooks and research pipelines, free for academic users and paid for commercial labs.

Benchling bet giving its platform free to academic researchers would build enough density and trust to convert commercial biologics labs into paying customers.

Founded 2012; raised $12.9M across three prior rounds including a Y Combinator-led angel round and an Andreessen Horowitz-led seed, then a Thrive Capital-led Series A in 2016, before the $14.5M Series B.

Sajith Wickramasekara co-founded Benchling in 2012 after watching research scientists in academic labs spend their time on what he called 'unscientific busywork' — reconciling paper research notebooks, tracking samples, and managing inventory with legacy software, offline spreadsheets and paper records that offered none of even the most basic functionality, like search. The company built a platform aimed at replacing that workflow, offering it free to academic users while building toward a commercial version for paid research labs.

Benchling raised $12.9M across three early rounds, including a Y Combinator-led angel round and a seed round led by Andreessen Horowitz, before Thrive Capital led its Series A in 2016. By its Series A, CEO Wickramasekara said the company had grown annual recurring revenue 500% year-over-year. On 2018-06-14, Benchling announced a $14.5M Series B led by Benchmark, with F-Prime Capital and returning investor Thrive Capital participating; Benchmark general partner Eric Vishria joined the board. By then, over 100,000 research scientists and lab personnel used Benchling across its free and paid offerings, and more than 80 companies — including Regeneron Pharmaceuticals, Incyte and Editas Medicine — used its enterprise version to standardize R&D processes.

Academic labs had no budget for enterprise software but ran the same workflow commercial biologics labs needed solved, making free access a training ground for future paid users.

A niche, deeply technical workflow like life sciences R&D rewards trust built through daily use, which a free academic tier could generate faster than a sales-led enterprise motion alone.

500% year-over-year ARR growth by the Series A gave Benchling concrete proof the free-to-paid conversion mechanism worked before it needed to raise a larger round.

A free tier isn't just a growth lever — for a niche professional workflow, it can be the distribution channel that turns individual users into the enterprise buyers who eventually pay.

As of 2018-06-14, Benchling had just closed its $14.5M Series B, served over 100,000 researchers across free and paid tiers, and counted more than 80 paying enterprise customers including Regeneron, Incyte and Editas Medicine.